The Cancer Genome Atlas

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

ALAMEDA, Calif. and CAMBRIDGE, England, Oct. 14, 2021 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer. The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target. 

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:00pm

Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.
  • STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline, said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Twist Alliance Pan-Cancer Methylation Panel Global Launch Event - A Strategic Collaboration Between AnchorDx and Twist Bioscience for Pan-Cancer Liquid Biopsy

Monday, October 11, 2021 - 2:00pm

The Pan-Cancer Panel wasdeveloped over a two-year period by AnchorDx incollaboration with Twist Bioscience (NASDAQ: TWST).

Key Points: 
  • The Pan-Cancer Panel wasdeveloped over a two-year period by AnchorDx incollaboration with Twist Bioscience (NASDAQ: TWST).
  • We developed a unique target enrichment-based approach to make methylation detection significantly better," said Emily Leproust, Ph.D., CEO and Co-founder of Twist Bioscience.
  • "The Twist Alliance Pan-Cancer Methylation Panel is a high-performance and cost-effective solution for comprehensive DNA methylation analysis.
  • AnchorDxand Twist Bioscience signed an agreement to co-market the Twist Alliance Pan-Cancer Methylation Panel globally.

BridGene Biosciences' IMTAC ™ Small Molecule Discovery Platform Featured in Multiple Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Thursday, October 7, 2021 - 2:05pm

The presentations detail the company's proprietary small molecule discovery platform, IMTACTM (Isobaric Mass Tagged Affinity Characterization) and its use in BridGene's latest discovery of therapeutic candidates and the identification of new targets for approved small-molecule drugs.

Key Points: 
  • The presentations detail the company's proprietary small molecule discovery platform, IMTACTM (Isobaric Mass Tagged Affinity Characterization) and its use in BridGene's latest discovery of therapeutic candidates and the identification of new targets for approved small-molecule drugs.
  • "This is among the most prominent scientific gatherings addressing drug discovery and molecular targets.
  • Overall, our presentations describe our IMTAC platform technology and its capabilities, the discovery of novel small-molecule inhibitors for undruggable targets, and the identification of previously unknown targets for approved small-molecule drugs."
  • BridGene used the IMTAC platform to screen its unique covalent library against live-cell proteomes and discovered small-molecule ligands for WDR5.

Twist Bioscience Expands Expert Custom Alliance Panel Offering

Tuesday, October 5, 2021 - 1:00pm

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced an expansion of its expert-led Alliance Panel product offering.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced an expansion of its expert-led Alliance Panel product offering.
  • Designed through collaboration with world-leading experts, Twist Alliance Panels combine validated content with Twist next-generation sequencing (NGS) workflow, target enrichment and DNA probes.
  • As the first Alliance Panel offering, Twist collaborated with the Regeneron Genetics Center LLC (RGC), a wholly-owned subsidiary of Regeneron, to develop the Twist Diversity SNP Panel , a custom NGS population genetics genotyping assay available to researchers globally for population genomics studies.
  • Today, Twist and AnchorDx launched the Twist Alliance Pan-cancer Methylation Panel based on The Cancer Genome Atlas (TCGA) database, including 31 cancer types and 47 TCGA database disease entities.

AnchorDx Develops New Liquid Biopsy Diagnostic Model for Early Detection of Breast Cancer

Monday, September 13, 2021 - 2:00pm

It can serve as a reliable approach for the early diagnosis of breast cancer and is expected to compensate for the deficiency of mammography.

Key Points: 
  • It can serve as a reliable approach for the early diagnosis of breast cancer and is expected to compensate for the deficiency of mammography.
  • Mammography-based screening (an X-ray picture of the breast) has contributed to a reduction in breast cancer mortality.
  • Therefore, novel and accurate detection methods in early breast cancer diagnosis are needed.
  • In order to compensate for the defects of mammography, AnchorDx conducted cfDNA methylation profiling to develop and validate a liquid biopsy-based breast cancer diagnostic test.

DNAnexus Strengthens Leadership Team with Appointment of Dr. Asha S. Collins as General Manager of Biobanks

Wednesday, September 8, 2021 - 1:03pm

DNAnexus, Inc. , the leading cloud-based biomedical and data management platform for healthcare and life sciences, today announced the appointment of Asha S. Collins, PhD, to General Manager, Biobanks.

Key Points: 
  • DNAnexus, Inc. , the leading cloud-based biomedical and data management platform for healthcare and life sciences, today announced the appointment of Asha S. Collins, PhD, to General Manager, Biobanks.
  • Dr. Collins will be responsible for managing the UK Biobank project and supporting the companys diverse global health research community.
  • View the full release here: https://www.businesswire.com/news/home/20210908005211/en/
    Asha S. Collins, PhD, General Manager of Biobanks at DNAnexus, Inc. (Photo: Business Wire)
    DNAnexus has built the cloud-based research analysis platform for UK Biobank, the worlds most comprehensive biomedical database.
  • Asha brings a breadth of unique international expertise and a proven track record of scaling biopharma businesses, said Richard Daly.

ImmixBio Announces Dr. George W. Sledge of Stanford University Medical Center Joins Scientific Advisory Board

Monday, August 9, 2021 - 1:38pm

LOS ANGELES, Aug. 9, 2021 /PRNewswire/ -- Immix Biopharma, Inc. ("ImmixBio"), a biotechnology company pioneering Tissue Specific Therapeutics (TSTx)TM for oncology and inflammation, today announced that George W. Sledge, MD, Professor of Medical Oncology and former Chief of Medical Oncology at Stanford University Medical Center has joined its Scientific Advisory Board.

Key Points: 
  • LOS ANGELES, Aug. 9, 2021 /PRNewswire/ -- Immix Biopharma, Inc. ("ImmixBio"), a biotechnology company pioneering Tissue Specific Therapeutics (TSTx)TM for oncology and inflammation, today announced that George W. Sledge, MD, Professor of Medical Oncology and former Chief of Medical Oncology at Stanford University Medical Center has joined its Scientific Advisory Board.
  • "I am thrilled to welcome Dr. George Sledge to our Scientific Advisory Board.
  • Dr. Sledge is a veteran clinical investigator and a true pioneer in treating metastatic cancers, including breast cancer," said Ilya Rachman, MD PhD, ImmixBio Founder & CEO.
  • is Professor and former Chief of Medical Oncology at Stanford University Medical Center.

Ashion Analytics to Present Data on the Value of Comprehensive Genomic Profiling of Gastrointestinal Cancers by Utilizing the GEM ExTra® Test

Friday, January 15, 2021 - 9:55am

Background: Gastrointestinal cancers (GIC) account for 26% of global cancer incidence and 35% of cancer-related deaths.

Key Points: 
  • Background: Gastrointestinal cancers (GIC) account for 26% of global cancer incidence and 35% of cancer-related deaths.
  • Methods: GEM ExTra assay was performed on 844 paired samples (ages 18-90 years, median= 61 years).
  • Overall, comprehensive genomic profiling enabled detection of established and novel actionable alterations, including fusions, which may have gone undetected using hotspot panels.
  • "Our study provides a comprehensive analysis of molecular signatures across 22 different gastrointestinal cancers using whole exome and whole transcriptome analysis.